Press releases

All Press releases are available in Swedish.

Cyxone change Certified Adviser

In accordance with the regulations on Nasdaq First North Stockholm, Cyxone uses a Certified Adviser (CA).

On the 1st December 2016 Cyxone changed the CA from Consensus Asset Management AB to Erik Penser Bank AB.

Contact
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: 070-716 80 09
E-mail: kjell.g.stenberg@cyxone.com
Adelgatan 21
221 22 Malmö
www.cyxone.com

This is information which Cyxone AB (publ) is required to publish under the EU Market Abuse Regulation. The information was provided by the auspices of the above contact person for publication on November 21, 2016 at. 09:02 CET.

About Cyxone
Cyxone AB (publ) is a biopharmaceutical company developing drugs based on cyclotides, a class of natural plant proteins. Cyclotide technology has the potential to provide new drugs offering beneficial pharmacological effects for diseases that currently lack effective and safe treatments. 
The company is focusing on the development of T20K, a substance which inhibits key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. 

August 30, 2017
Regulatory

Summary of interim report

Period (2017-01-01-2017-06-30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -4 075 (-1 626)
  • Earnings per share -0,27 (-0,13) SEK
  • Cash and cash equivalents, KSEK 28 114 (24 636) as of 2017-06-30
  • Equity ratio 95,2 (87,9) % as of 2017-06-30

Period (2017-04-01-2017-06-30)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -2 588 (-1 157)
  • Earnings per share SEK -0,17 (-0,09) 
Read more
June 14, 2017

Cyxone signs acquisition agreement for candidate drug in Phase 2 Cyxone can announce today that the company has signed an agreement pertaining to the exclusive rights to acquire the clinical candidate drug Rabeximod from OxyPharma AB. The transaction has been structured so as to minimise the impact on Cyxone's cash flow by offering the seller 1,916,372 shares, (one million, nine hundred and sixteen thousand, three hundred and seventy two shares amounting to a dilution of 12.5 per cent), as well as royalty rights amounting to ten (10) per cent of future net earnings from Rabeximod. Cyxone will call an extraordinary general meeting to seek shareholder approval for a directed new share issue. This will pave the way for the acquisition and a Phase 2b-study in rheumatoid arthritis.

Read more
June 07, 2017

Cyxone AB and the University of Queensland in Australia are launching a co- operation agreement to continue studies into the effects of Cyxone's T20K development substance in combating MS.

Read more
May 18, 2017

Cyxone can announce today that it has established a long-term strategic co-operation agreement with Sourcia, a clinical contract research organization (CRO) with offices in Belgium, Germany, and the Netherlands.

Read more
May 16, 2017
Regulatory

Period (2017-01-01-2017-03-31)

  • Operating revenue KSEK 0 (0)
  • Income after financial items KSEK -1491 (-307)
  • Earnings per share -0,10 (-0,04) SEK
  • Cash and cash equivalents (2017-03-31) 31 275 (4 114) KSEK
  • Equity ratio 98,2 (97,8) % as of 2017-03-31
Read more
May 15, 2017

Since 2016, Cyxone AB and Swiss pharmaceutical manufacturer Bachem AG have worked closely on the production of syntheses of Cyxone's development substance T20K, and on the production of substances for studies that started last year.

Read more
March 10, 2017
Regulatory

Cyxone can announce today that an independent research group at Monash University in Australia has confirmed the positive effects of the company's development substance T20K on multiple sclerosis (MS) symptoms in animal models as previously described.

Read more
December 21, 2016
Regulatory

Today, Cyxone announce that they will acquire the entire family of patents protecting the Company's main candidate T20K, from the Medical University of Vienna. The cost of € 100,930 includes VAT and corresponds to the costs of the patenting process.

Read more
December 19, 2016
Regulatory

Cyxone announce that T20K demonstrates no measurable toxic effect in mice after oral administration of up to 100 mg/kg in a single dose.  Even at an oral dose of 250 mg/kg, half of the animals recovered well after treatment. Low toxicity of injected T20K has previously been reported by Cyxone.

Read more
November 21, 2016
Regulatory

In accordance with the regulations on Nasdaq First North Stockholm, Cyxone uses a Certified Adviser (CA).

Read more
1
2